Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis.

ABSTRACT:

Background

The first- and second-trimester screening for trisomy 21 (T21) are reimbursed for all pregnant women in Belgium. Using a cut-off risk of 1:300 for T21, about 5% of all pregnant women are referred for definitive prenatal diagnosis using an invasive test, at a sensitivity of (only) 72.5%. The sensitivity and specificity of the non-invasive prenatal test (NIPT) are over 99% but come at a cost of €460 (£373) per test. The objective is to estimate the consequences of introducing NIPT for the detection of T21.

Methods

A cost-consequences analysis was performed presenting the impact on benefits, harms and costs. Context-specific real-world information was available to set up a model reflecting the current screening situation in Belgium. This model was used to construct t

SUBMITTER: Neyt M 

PROVIDER: S-EPMC4225226 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature